Details of the Drug Combination

General Information of Drug Combination (ID: DCGX3N2)

• Drug Combination Name: MK-5108 + RTB101
• Indication: Adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  MK-5108 (DMFGYKS): Small molecular drug
  RTB101 (DM62QTW): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: CAOV3
  Zero Interaction Potency (ZIP) Score: 4.62
  Bliss Independence Score: 5.27
  Loewe Additivity Score: 7.06
  LHighest Single Agent (HSA) Score: 11.05

Molecular Interaction Atlas of This Drug Combination

Indication(s) of MK-5108

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

MK-5108 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Aurora kinase B (AURKB)	TT5LS6T	AURKB_HUMAN	Inhibitor	[5]
Aurora kinase A (AURKA)	TTPS3C0	AURKA_HUMAN	Inhibitor	[5]

Indication(s) of RTB101

Disease Entry	ICD 11	Status	REF
Respiratory tract infection	CA45	Phase 3	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]

RTB101 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
CREB-regulated transcription coactivator 1 (TORC1)	TT4GO0F	CRTC1_HUMAN	Inhibitor	[6]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour	DCTOAFZ	ES2	Investigative	[7]
Breast and ovarian cancer syndrome	DCPWM10	UWB1289	Investigative	[8]
Breast and ovarian cancer syndrome	DCI8VGW	UWB1289+BRCA1	Investigative	[8]
Breast carcinoma	DCJ0R7O	OCUBM	Investigative	[8]
Carcinoma	DC0MBUE	EFM192B	Investigative	[8]
Carcinoma	DCJSAE3	MDAMB436	Investigative	[8]
Colon adenocarcinoma	DCG5Z5Q	LOVO	Investigative	[8]
Invasive ductal carcinoma	DCPB7L4	T-47D	Investigative	[8]
Adenocarcinoma	DC38E6Y	A427	Investigative	[1]
Adenocarcinoma	DC3ZAIZ	NCIH2122	Investigative	[1]
Adenocarcinoma	DCWSQJO	NCIH520	Investigative	[1]
Adenocarcinoma	DCFXDSX	HT29	Investigative	[1]
Amelanotic melanoma	DC2YLWS	A2058	Investigative	[1]
Germ cell tumour	DC6RGCD	PA1	Investigative	[1]
Malignant melanoma	DCNKF7S	HT144	Investigative	[1]
Malignant melanoma	DCJT0W2	RPMI7951	Investigative	[1]
Malignant melanoma	DCHAO2N	SKMEL30	Investigative	[1]
Malignant melanoma	DCD44TR	UACC62	Investigative	[1]
Mesothelioma	DCSM853	MSTO	Investigative	[1]
Non small cell carcinoma	DCZEFPF	SKMES1	Investigative	[1]
Ovarian endometrioid adenocarcinoma	DCHAJJC	A2780	Investigative	[1]
Prostate carcinoma	DC9I9LM	VCAP	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] ClinicalTrials.gov (NCT00543387) Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
• [5] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [6] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [7] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [8] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.